Eculizumab
Title: Eculizumab
CAS Registry Number: 219685-50-4
CAS Name: Anti-(human complement C5a-chain)(human-mouse monoclonal 5G1.1 heavy chain)immunoglobulin, disulfide with human-mouse monoclonal 5G1.1 light chain, dimer
Additional Names: h5G1.1 Fab; h5G1.1VHC + h5G1.1VLC
Literature References: Humanized monoclonal antibody directed against complement component C5; designed to prevent activation of complement-mediated inflammation and tissue injury. Prepn: M. J. Evans et al., WO 9529697; eidem, US 6355245 (1995, 2002 both to Alexion); and complement inhibition study: T. C. Thomas et al., Mol. Immunol. 33, 1389 (1996). Clinical evaluation in paroxysmal nocturnal hemoglobinuria: P. Hillmen et al., N. Engl. J. Med. 350, 552 (2004); A. Hill et al., Blood 106, 2559 (2005). Review of development and therapeutic potential: M. Kaplan, Curr. Opin. Invest. Drugs 3, 1017-1023 (2002).
Therap-Cat: Anti-inflammatory.
Keywords: Anti-inflammatory (Biological Response Modifier).

Others monographs:
4-EthylpyridineEthyl Maltol1-Amino-2-naphthol-4-sulfonic AcidCymoxanil
Boric AcidBosentanAcetaldehydeAllyl Ethyl Ether
CitronellalHypoxanthineGold TrioxideProtiofate
SparfloxacinSemicarbazide Hydrochlorideβ-CitronellolTizanidine
©2016 DrugLead US FDA&EMEA